Company / Depreciation & Amortization
Veracyte, Inc. Depreciation & Amortization History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$21.4M
FY2025
5-year range
$19.6M / $27.2M
FY2021-FY2025
Trend
-8.7%
vs FY2024
Sector context
#95 of 135
Health Care
What the data says
At $21M, Veracyte, Inc.'s depreciation & amortization ranks #41 of 135 in the Health Care sector. Improved from $27M to $21M over the past 2 years.
Based on SEC 10-K filings.
$21M in FY2025 with a 5-year CAGR of +21.9%.
Improved from $27M to $21M over the past 2 years.
Health Care sector context is included.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- -6.2%
- 5-Year CAGR
- +21.9%
- 10-Year CAGR
- -
Sector benchmark
#41 of 135 in Health CareTop 30% of 135This company $21.4M Sector average $334.5M
▼
-93.6% below sector average
Key checks
Key Insights
- 5-year CAGR of +21.9%, indicating consistent growth.
- In FY2025, depreciation & amortization decreased 8.7% year-over-year.
- Ranks #95 out of 135 companies in the Health Care sector.
- Peak depreciation & amortization was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score 6.19 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $21.4M | -8.7% |
| FY2024 | $23.5M | -13.7% |
| FY2023 | $27.2M | +4.9% |
| FY2022 | $25.9M | +32.3% |
| FY2021 | $19.6M | +146.6% |
| FY2020 | $7.9M | +93.0% |
| FY2019 | $4.1M | +5.0% |
| FY2018 | $3.9M | +2.1% |
| FY2017 | $3.8M | +9.4% |
| FY2016 | $3.5M | +55.8% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026